TrialCurveKEYNOTE-671 (stage II subgroup): reconstructed Kaplan–Meier curves
A Subgroup Analysis of Perioperative Pembrolizumab in Clinical Stage II Non-Small-Cell Lung Cancer from the Randomized KEYNOTE-671 Study. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Eur J Cardiothorac Surg. 2026 Mar 24;68(3):ezag028. doi: 10.1093/ejcts/ezag028 |
|---|---|
| DOI | 10.1093/ejcts/ezag028 |
| Registry | NCT03425643 |
| Phase | Phase 3 |
| Conditions | Non-small Cell Lung Cancer |
| Interventions | Pembrolizumab, Placebo, Cisplatin, Gemcitabine, Pemetrexed |
| Sponsor | Merck Sharp & Dohme LLC |
| Enrolment | 797 |
| Source licence | Figure published under CC BY 4.0 |
Event-free survival — Clinical stage II NSCLC
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Pembro arm not reached; Neoadjuvant chemo only arm 22.7 months. Survival at 18 months: Pembro arm 77%; Neoadjuvant chemo only arm 66%. Hazard ratio Pembro arm vs Neoadjuvant chemo only arm 0.50 (95% CI 0.34–0.74).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Pembro arm | 118 | 40 | not reached |
| Neoadjuvant chemo only arm | 121 | 71 | 22.7 |
- Pembro arm vs Neoadjuvant chemo only arm: reconstructed HR 0.50 (95% CI 0.34–0.74)
Landmark survival (reconstructed)
| Time | Pembro arm | Neoadjuvant chemo only arm |
|---|---|---|
| 6 mo | 90.6% | 87.2% |
| 12 mo | 82.0% | 73.4% |
| 18 mo | 76.7% | 66.5% |
| 24 mo | 72.3% | 49.9% |
| 36 mo | 66.7% | 42.8% |
| 48 mo | 64.1% | 38.1% |
| 60 mo | 64.1% | 32.5% |
Checks against the published figure
- Neoadjuvant chemo only arm median: printed 24.4, reconstructed 22.7 pass
- hazard ratio (direction inferred): printed 0.5, reconstructed 0.5 pass
Event-free survival — Clinical stage IIA NSCLC
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Pembro arm not reached; Neoadjuvant chemo only arm 31.6 months. Survival at 18 months: Pembro arm 82%; Neoadjuvant chemo only arm 74%. Hazard ratio Pembro arm vs Neoadjuvant chemo only arm 0.50 (95% CI 0.20–1.30).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Pembro arm | 22 | 7 | not reached |
| Neoadjuvant chemo only arm | 19 | 11 | 31.6 |
- Pembro arm vs Neoadjuvant chemo only arm: reconstructed HR 0.50 (95% CI 0.20–1.30)
Landmark survival (reconstructed)
| Time | Pembro arm | Neoadjuvant chemo only arm |
|---|---|---|
| 6 mo | 95.5% | 89.5% |
| 12 mo | 86.4% | 78.9% |
| 18 mo | 81.8% | 73.7% |
| 24 mo | 77.3% | 57.9% |
| 36 mo | 67.6% | 47.4% |
| 48 mo | 67.6% | 37.9% |
Checks against the published figure
- Neoadjuvant chemo only arm median: printed 31.8, reconstructed 31.6 pass
- hazard ratio (direction inferred): printed 0.5, reconstructed 0.505 pass
Event-free survival — Clinical stage IIB NSCLC
From figure panel C · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Pembro arm not reached; Neoadjuvant chemo only arm 22.4 months. Survival at 18 months: Pembro arm 76%; Neoadjuvant chemo only arm 65%. Hazard ratio Pembro arm vs Neoadjuvant chemo only arm 0.51 (95% CI 0.33–0.78).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Pembro arm | 96 | 33 | not reached |
| Neoadjuvant chemo only arm | 102 | 60 | 22.4 |
- Pembro arm vs Neoadjuvant chemo only arm: reconstructed HR 0.51 (95% CI 0.33–0.78)
Landmark survival (reconstructed)
| Time | Pembro arm | Neoadjuvant chemo only arm |
|---|---|---|
| 6 mo | 89.5% | 86.8% |
| 12 mo | 80.9% | 72.3% |
| 18 mo | 75.5% | 65.1% |
| 24 mo | 71.2% | 48.6% |
| 36 mo | 66.6% | 42.3% |
| 48 mo | 63.4% | 38.6% |
| 60 mo | 63.4% | 32.6% |
Checks against the published figure
- Neoadjuvant chemo only arm median: printed 22.4, reconstructed 22.4 pass
- hazard ratio (direction inferred): printed 0.51, reconstructed 0.508 pass
Overall survival — Participants with clinical stage II NSCLC
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Pembro arm not reached; Neoadjuvant chemo only arm not reached. Survival at 18 months: Pembro arm 86%; Neoadjuvant chemo only arm 86%. Hazard ratio Pembro arm vs Neoadjuvant chemo only arm 0.69 (95% CI 0.43–1.11).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Pembro arm | 118 | 29 | not reached |
| Neoadjuvant chemo only arm | 121 | 42 | not reached |
- Pembro arm vs Neoadjuvant chemo only arm: reconstructed HR 0.69 (95% CI 0.43–1.11)
Landmark survival (reconstructed)
| Time | Pembro arm | Neoadjuvant chemo only arm |
|---|---|---|
| 6 mo | 94.9% | 98.3% |
| 12 mo | 90.7% | 92.5% |
| 18 mo | 86.4% | 85.8% |
| 24 mo | 82.2% | 79.0% |
| 36 mo | 77.8% | 69.8% |
| 48 mo | 75.8% | 66.3% |
| 60 mo | 75.8% | 59.8% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.69, reconstructed 0.691 pass
Overall survival — Participants with clinical stage IIA NSCLC
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Pembro arm not reached; Neoadjuvant chemo only arm not reached. Survival at 18 months: Pembro arm 86%; Neoadjuvant chemo only arm 84%. Hazard ratio Pembro arm vs Neoadjuvant chemo only arm 0.58 (95% CI 0.19–1.84).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Pembro arm | 22 | 5 | not reached |
| Neoadjuvant chemo only arm | 19 | 7 | not reached |
- Pembro arm vs Neoadjuvant chemo only arm: reconstructed HR 0.58 (95% CI 0.19–1.84)
Landmark survival (reconstructed)
| Time | Pembro arm | Neoadjuvant chemo only arm |
|---|---|---|
| 6 mo | 95.5% | 100.0% |
| 12 mo | 86.4% | 94.7% |
| 18 mo | 86.4% | 83.6% |
| 24 mo | 81.8% | 78.0% |
| 36 mo | 77.3% | 61.3% |
| 48 mo | 77.3% | 61.3% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.61, reconstructed 0.585 pass
Overall survival — Participants with clinical stage IIB NSCLC
From figure panel C · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Pembro arm not reached; Neoadjuvant chemo only arm not reached. Survival at 18 months: Pembro arm 86%; Neoadjuvant chemo only arm 87%. Hazard ratio Pembro arm vs Neoadjuvant chemo only arm 0.71 (95% CI 0.42–1.19).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Pembro arm | 96 | 24 | not reached |
| Neoadjuvant chemo only arm | 102 | 35 | not reached |
- Pembro arm vs Neoadjuvant chemo only arm: reconstructed HR 0.71 (95% CI 0.42–1.19)
Landmark survival (reconstructed)
| Time | Pembro arm | Neoadjuvant chemo only arm |
|---|---|---|
| 6 mo | 94.8% | 98.0% |
| 12 mo | 91.7% | 93.1% |
| 18 mo | 86.4% | 87.1% |
| 24 mo | 82.2% | 79.0% |
| 36 mo | 78.0% | 71.0% |
| 48 mo | 75.5% | 66.8% |
| 60 mo | 75.5% | 59.3% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.71, reconstructed 0.706 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Related trials
- ETER701: Overall survival; Progression-free survival (PFS)
- Socazolimab + chemotherapy in extensive-stage SCLC: Overall survival; Progression-free survival (IRRC, RECIST v1.1)
- Rezivertinib in EGFR-mutated NSCLC with CNS metastases: CNS progression-free survival (BICR)
- PRESERVE-003: Overall survival (OS); Progression-free survival (PFS, investigator assessment)
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials